RecruitingPhase 2NCT05571059

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Sponsor

Cumberland Pharmaceuticals

Enrollment

128 participants

Start Date

Jan 31, 2024

Study Type

INTERVENTIONAL

Conditions

Idiopathic Pulmonary Fibrosis

Summary

Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF.

Eligibility

Min Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ifetroban Sodium and a drug called Placebo for people with idiopathic pulmonary fibrosis. The study is currently recruiting participants at 19 locations. People eligible for this study include aged 40 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGIfetroban Sodium

Once daily oral ifetroban

DRUGPlacebo

Matching oral placebo

Locations(20)

Biosolutions Clinical Research

La Mesa, California, United States

University of California San Francisco

San Francisco, California, United States

UConn Health

Farmington, Connecticut, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

Miami VA Health System

Miami, Florida, United States

Northwestern Medicine

Chicago, Illinois, United States

Indiana University Health

Indianapolis, Indiana, United States

University of Kansas

Kansas City, Kansas, United States

University of Louisville

Louisville, Kentucky, United States

Beaumont Hospital, Royal Oak

Royal Oak, Michigan, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

University of Rochester

Rochester, New York, United States

UNC Chapel Hill

Chapel Hill, North Carolina, United States

Bend Memorial Hospital

Bend, Oregon, United States

Temple University Hospital

Philadelphia, Pennsylvania, United States

Avera Research Institute

Sioux Falls, South Dakota, United States

Pulmonary & Sleep Specialists

Dickson, Tennessee, United States

Baylor University Medical Center

Dallas, Texas, United States

Premier Pulmonary Critical Care and Sleep Medicine

Denison, Texas, United States

UW Health University Hospital

Madison, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05571059

Related Trials

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

NCT0728445953 locations

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

NCT072302886 locations

A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

NCT075169511 location

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT0703652346 locations

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

NCT003738411 location